Menu

Myeloproliferative Neoplasms: Diagnosis and Treatment

Moving in Cancer Discovery.

Moved, week to 23 Oct 2026: 1
Papers in 60 days: 10

Add Myeloproliferative Neoplasms: Diagnosis and Treatment as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 12:56 pm AEDT

Moved this week

Everything that moved →

Type II JAK2 Inhibitor Gets Off to a Strong Start.
Cancer Discovery · 1 July 2026 · News
AJ1-11095, a type II JAK2 inhibitor, produced impressive clinical responses in a phase I study for myelofibrosis, indicating potential advantages over existing inhibitors.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42381481
Open in JClub

Latest in Myeloproliferative Neoplasms: Diagnosis and Treatment

Newest first · last 60 days

TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
Blood · 15 Oct 2026 · Clinical Trial, Phase III
Navitoclax plus ruxolitinib significantly increases the proportion of patients with ≥35% spleen volume reduction at week 24 in untreated myelofibrosis, reaching 63.2% versus 31.5%.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42378247
Open in JClub
Characterization of disease-initiating hematopoietic stem cells in calreticulin-mutated myeloproliferative neoplasms.
Blood · 25 Sept 2026 · Journal Article
CALR-mutated myeloproliferative neoplasms originate mainly from expansion of Vwf-positive, platelet-biased hematopoietic stem cells, with CALRdel52 mutations showing greater amplification.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42789459
Open in JClub
Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.
Blood · 24 Sept 2026 · Journal Article
Fibrocytes are the main collagen-producing cells in JAK2V617F-mutated myelofibrosis, accounting for nearly two-thirds of collagen production in the bone marrow.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42391645
Open in JClub
Distinct Somatic Mutational Landscapes in Paired Blood and Arterial Tissues in Coronary Artery Disease
medRxiv · 23 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.21.26363617
Open in JClub
First-line ibrutinib plus venetoclax for MCL.
Blood · 17 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42752832
Open in JClub
Type-I interferon-activated NK cells control polycythemia vera in vivo.
Blood · 10 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42233405
Open in JClub
Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.
Cancer Discovery · 1 Sept 2026 · Journal Article
Genomic evolution in myeloproliferative neoplasms reveals distinct pathways to disease progression and therapy-related mutagenesis.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42008361
Open in JClub
The Evolution of Polyclonal Competition in Aging Hematopoiesis.
Cancer Discovery · 1 Sept 2026 · Journal Article
Polyclonal competition drives clonal hematopoiesis, with about 3 fit clones entering the HSC pool annually and rarely exceeding 5% frequency, mainly emerging later in life.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42084533
Open in JClub
MHC II-expressing bone marrow megakaryocytes are noncanonical antigen presenting cells and activate CD4+ T cells ex vivo
bioRxiv · 27 Aug 2026 · Preprint
Read the AI summary in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.11.21.689743
Open in JClub
Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.
Blood · 27 Aug 2026 · Journal Article
Aberrant splicing of MBD1 produces the MBD1-L isoform, driving myelodysplastic syndromes (MDS) by reshaping the epigenome and causing hematopoietic defects in humans.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42322117
Open in JClub

Add Myeloproliferative Neoplasms: Diagnosis and Treatment as an interest in JClub

Get JClub on Google Play

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

By field

All journals by field →